Favipiravir pharmacokinetics in Thai adults with mild COVID‐19: A sub‐study of interpatient variability and ethnic differences in exposure

Documenti analoghi

• Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function
  di: Wei Yin, et al.
  Pubblicazione: (2024)
• The preclinical pharmacokinetics of Tolinapant—A dual cIAP1/XIAP antagonist with in vivo efficacy
  di: Vanessa Martins, et al.
  Pubblicazione: (2024)
• Population Pharmacokinetics and Pharmacodynamics of Sitafloxacin in Plasma and Alveolar Epithelial Lining Fluid of Critically Ill Thai Patients With Pneumonia
  di: Taniya Paiboonvong, et al.
  Pubblicazione: (2025)
• Population pharmacokinetics and exposure‐response relationship for temsavir following fostemsavir administration in treatment‐experienced HIV patients
  di: Ridhi Parasrampuria, et al.
  Pubblicazione: (2025)
• Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: Alterations of gene expression, microsomal activity, and pharmacokinetics
  di: Genki Minegishi, et al.
  Pubblicazione: (2024)